KRAS and colorectal carcinoma: Dot blot assays confirmed that SLC25A21 overexpression increased the abundance of 5-hmC marks to equal that observed with α-KG addition, and this effect was restored by treatment with Bobcat33, a TET1/2 inhibitor (29), in KRAS-mutant CRC cells (Figure 7B).